Ticker brief
LBRX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
+0.33
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-12 · now +0.40 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @ScalpIdeas | C | · | 1 | -0.40 |
| @Brad_E_Schulz | C | · | 1 | +0.30 |
| @OzmosiHealth | C | · | 1 | +0.20 |
| @AlertsAndNews | C | -3.92 | 1 | +0.25 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-12 | @Quantumup1 | +0.40 | Guggenheim reiterated LBRX as a Best Idea with Buy rating and $80 target. | · | tweet ↗ |
| 2026-10-11 | @AlertsAndNews | +0.25 | LB Pharmaceuticals presented preclinical data supporting LB-102's mechanism and highlighted late-stage programs. | · | tweet ↗ |
| 2026-10-10 | @OzmosiHealth | +0.20 | Reports new preclinical LB-102 mechanism data and ongoing late-stage programs. | · | tweet ↗ |
| 2026-10-09 | @Brad_E_Schulz | +0.30 | Reports intraday sector breadth and qualifying biotech movers. | · | tweet ↗ |
| 2026-10-05 | @ScalpIdeas | -0.40 | Roth downgraded LBRX to Neutral from Buy. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.